Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease

BMC Systems Biology

Volumn 6, Issue , 2012, Pages

  Chavali, Arvind K ^a   Blazier, Anna S ^a   Tlaxca, Jose L ^a   Jensen, Paul A ^a   Pearson, Richard D ^b   Papin, Jason A ^a,c  

^a University of Virginia   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEISHMANIA MAJOR;

ANTIMALARIAL AGENT; HALOFANTRINE; PHENANTHRENE DERIVATIVE;

ARTICLE; DRUG DELIVERY SYSTEM; FOOD AND DRUG ADMINISTRATION; GENETICS; HUMAN; LEISHMANIA MAJOR; METABOLISM; NEGLECTED DISEASE; SKIN LEISHMANIASIS; UNITED STATES;

ANTIMALARIALS; DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; METABOLIC NETWORKS AND PATHWAYS; NEGLECTED DISEASES; PHENANTHRENES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860222515     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-6-27     Document Type: Article

References (54)

1. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009, 373(9674):1570-1575. 10.1016/S0140-6736(09)60233-6, 19410718.
2. Hotez PJ. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin Pharmacol Ther 2009, 85(6):659-664. 10.1038/clpt.2009.16, 19322166.
3. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004, 27(5):305-318. 10.1016/j.cimid.2004.03.004, 15225981.
4. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003, 19(11):502-508. 10.1016/j.pt.2003.09.008, 14580961.
5. Molyneux D, Killick-Kendrick R. Morphology, ultrastructure and life cycles. The Leishmaniases in Biology and Medicine 1987, 1:121-176. London: Academic Press Inc, Peters W, Killick-Kendrick R.
6. Hotez PJ, Molyneux DH, Fenwick A, Savioli L, Takeuchi T. A Global Fund to Fight Neglected Tropical Diseases: is the G8 Hokkaido Toyako 2008 Summit ready?. PLoS Negl Trop Dis 2008, 2(3):e220. 10.1371/journal.pntd.0000220, 2268747, 18365038.
7. Caffrey CR, Steverding D. Recent initiatives and strategies to developing new drugs for tropical parasitic diseases. Expert Opin on Drug Discov 2008, 3(2):173-186.
8. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002, 2(8):494-501. 10.1016/S1473-3099(02)00347-X, 12150849.
9. Plata G, Hsiao TL, Olszewski KL, Llinas M, Vitkup D. Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network. Mol Syst Biol 2010, 6:408. 2964117, 20823846.
10. Jamshidi N, Palsson BO. Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets. BMC Syst Biol 2007, 1:26. 10.1186/1752-0509-1-26, 1925256, 17555602.
11. Chavali AK, Whittemore JD, Eddy JA, Williams KT, Papin JA. Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major. Mol Syst Biol 2008, 4:177. 2290936, 18364711.
12. Oberhardt MA, Palsson BO, Papin JA. Applications of genome-scale metabolic reconstructions. Mol Syst Biol 2009, 5:320. 2795471, 19888215.
13. Dumas C, Ouellette M, Tovar J, Cunningham ML, Fairlamb AH, Tamar S, Olivier M, Papadopoulou B. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 1997, 16(10):2590-2598. 10.1093/emboj/16.10.2590, 1169870, 9184206.
14. Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis of antimony treatment in leishmaniasis. J Med Chem 2009, 52(8):2603-2612. 10.1021/jm900185q, 19317451.
15. Jockers-Scherubl MC, Schirmer RH, Krauth-Siegel RL. Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds. Eur J Biochem 1989, 180(2):267-272. 10.1111/j.1432-1033.1989.tb14643.x, 2647489.
16. Heby O, Persson L, Rentala M. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids 2007, 33(2):359-366. 10.1007/s00726-007-0537-9, 17610127.
17. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004, 53(2):158-166. 10.1093/jac/dkh058, 14729756.
18. Olliaro PL, Bryceson AD. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993, 9(9):323-328. 10.1016/0169-4758(93)90231-4, 15463794.
19. Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 2004, 10(6):307-315. 10.1007/s10156-004-0348-9, 15614453.
20. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 2007, 14(10):1153-1169. 10.2174/092986707780362862, 17456028.
21. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992, 165(3):528-534. 10.1093/infdis/165.3.528, 1311351.
22. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002, 346(12):891-895. 10.1056/NEJMoa011882, 11907288.
23. Larbi EB, al-Khawajah A, al-Gindan Y, Jain S, Abahusain A, al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. AmJTrop Med Hyg 1995, 52(2):166-168.
24. Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int J Parasitol 1996, 26(12):1413-1415. 10.1016/S0020-7519(96)00128-2, 9024895.
25. Bahamdan KA, Tallab TM, Johargi H, Nourad MM, Ibrahim K, el Sherbini AH, Karkashan E, Khare AK, Nauri MM. Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 1997, 36(1):59-60. 10.1046/j.1365-4362.1997.00021.x, 9071621.
26. Mishra M, Thakur BD, Choudhary M. Metronidazole and Indian kala-azar: results of a clinical trial. Br Med J (Clin Res Ed) 1985, 291(6509):1611.
27. Buckner FS. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol 2008, 625:61-80. 10.1007/978-0-387-77570-8_6, 18365659.
28. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992, 126(Suppl 39):2-7.
29. Marriott MS. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J Gen Microbiol 1980, 117(1):253-255.
30. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002, 27(7):571-577. 10.1046/j.1365-2230.2002.01151.x, 12464152.
31. Vicens Q, Westhof E. Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure 2001, 9(8):647-658. 10.1016/S0969-2126(01)00629-3, 11587639.
32. Fernandez MM, Malchiodi EL, Algranati ID. Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob Agents Chemother 2011, 55(1):86-93. 10.1128/AAC.00506-10, 3019668, 20956601.
33. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002, 3(4):538-544.
34. Wasunna MK, Rashid JR, Mbui J, Kirigi G, Kinoti D, Lodenyo H, Felton JM, Sabin AJ, Albert MJ, Horton J. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. AmJTrop Med Hyg 2005, 73(5):871-876.
35. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, Nam J, Jang J, Cechetto J, Lee CB, Moon S, et al. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis 2010, 4(5):e675. 10.1371/journal.pntd.0000675, 2864270, 20454559.
36. St George S, Bishop JV, Titus RG, Selitrennikoff CP. Novel compounds active against Leishmania major. Antimicrob Agents Chemother 2006, 50(2):474-479. 10.1128/AAC.50.2.474-479.2006, 1366913, 16436699.
37. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, Mustata G, Wipf P, Johnson J, O'Neil M, Grogl M, et al. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 2009, 3(11):e540. 10.1371/journal.pntd.0000540, 2765639, 19888337.
38. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, Chiang PK, Wolff B, Guy KR, Williams J, et al. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des 2006, 67(5):355-363. 10.1111/j.1747-0285.2006.00389.x, 16784460.
39. Doherty TM, Sher A, Vogel SN. Paclitaxel (Taxol)-induced killing of Leishmania major in murine macrophages. Infect Immun 1998, 66(9):4553-4556. 108557, 9712819.
40. Manzano JI, Carvalho L, Perez-Victoria JM, Castanys S, Gamarro F. Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major. Antimicrob Agents Chemother 2011, 55(3):1045-1052. 10.1128/AAC.01545-10, 3067095, 21199921.
41. Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, Legros F. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J 2009, 8:289. 10.1186/1475-2875-8-289, 2801676, 20003315.
42. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF, Staunton JE, Jin X, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009, 27(7):659-666. 10.1038/nbt.1549, 2708317, 19581876.
43. WHO Guidelines for the treatment of malaria (2nd ed.) 2010, Geneva, Switzerland: WHO Press, World Health Organization, 2, WHO.
44. Raman K, Yeturu K, Chandra N. TargetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis. BMC Syst Biol 2008, 2:109. 10.1186/1752-0509-2-109, 2651862, 19099550.
45. Shen Y, Liu J, Estiu G, Isin B, Ahn YY, Lee DS, Barabasi AL, Kapatral V, Wiest O, Oltvai ZN. Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc Natl Acad Sci USA 2010, 107(3):1082-1087. 10.1073/pnas.0909181107, 2824290, 20080587.
46. Kim HU, Kim SY, Jeong H, Kim TY, Kim JJ, Choy HE, Yi KY, Rhee JH, Lee SY. Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol Syst Biol 2011, 7:460. 3049409, 21245845.
47. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007, 448(7154):645-646. 10.1038/448645a, 17687303.
48. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan AW, Chen F, et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 2008, 7(11):900-907. 10.1038/nrd2684, 3184002, 18927591.
49. Mahadevan R, Schilling CH. The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. Metab Eng 2003, 5(4):264-276. 10.1016/j.ymben.2003.09.002, 14642354.
50. Goldoni M, Johansson C. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro 2007, 21(5):759-769. 10.1016/j.tiv.2007.03.003, 17420112.
51. de Oliveira-Silva F, de Morais-Teixeira E, Rabello A. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. AmJTrop Med Hyg 2008, 78(5):745-749.
52. Mikus J, Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 2000, 48(3):265-269. 10.1016/S1383-5769(99)00020-3, 11227767.
53. Shimony O, Jaffe CL. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods 2008, 75(2):196-200. 10.1016/j.mimet.2008.05.026, 18573286.
54. Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol Biochem Parasitol 2002, 125(1-2):35-45. 10.1016/S0166-6851(02)00206-2, 12467972.